Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE
Companies in the News
Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells,...
- May 31
Gritstone Announces Updated Overall Survival Results in CRC Patients from Phase 1/2 Study of GRANITE
Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy...
- Apr 19
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known...
- Apr 12
Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing
Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by...
- Jan 24
eFFECTOR Therapeutics Provides Pipeline and Business Updates
Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer...
- Jan 20
Nuvation Bio Announces FDA Clearance of IND Application for NUV-868 for the Advanced Solid Tumors
NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...
- Jan 6
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion...
- Dec 4, 2021
Landus and Indigo Join Forces to Elevate Farmers’ Profitable Role in Digital Ag Landscape
Landus farmers will gain access to new carbon revenue stream and digital grain marketing tools AMES, Iowa (December 2, 2021) – Landus,...
- Nov 19, 2021
Generate Biomedicines Announces Raise of $370 Million to Advance its Drug Generation Platform
Cambridge, Mass, November 18, 2021 – Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent...